{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:27:12Z","timestamp":1787682432516,"version":"build-2784847793"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03192-4","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T07:00:53Z","timestamp":1766559653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["KMT2A-Mediated transcriptional regulation in stemness and cancer: molecular mechanisms and therapeutic opportunities"],"prefix":"10.1007","volume":"43","author":[{"given":"Md Shiblee Sadik","family":"Sabuj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanvir","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Jamilur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M. Abdus","family":"Salam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-9353","authenticated-orcid":false,"given":"Md Rashedunnabi","family":"Akanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"issue":"1","key":"3192_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40364-025-00786-y","volume":"13","author":"S Zehtabcheh","year":"2025","unstructured":"Zehtabcheh S, Soleimani Samarkhazan H, Asadi M, Zabihi M, Parkhideh S, Mohammadi MH. Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies. Biomark Res. 2025;13(1):73.","journal-title":"Biomark Res"},{"key":"3192_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrrev.2022.108443","volume":"790","author":"E Poreba","year":"2022","unstructured":"Poreba E, Lesniewicz K, Durzynska J. Histone\u2013lysine N-methyltransferase 2 (KMT2) complexes\u2013a new perspective. Mutat Res Rev Mutat Res. 2022;790:108443.","journal-title":"Mutat Res Rev Mutat Res"},{"issue":"2","key":"3192_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.tcb.2024.06.001","volume":"35","author":"H Wang","year":"2025","unstructured":"Wang H, Helin K. Roles of H3K4 methylation in biology and disease. Trends Cell Biol. 2025;35(2):115\u201328.","journal-title":"Trends Cell Biol"},{"key":"3192_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcped.2024.100204","volume":"4","author":"RS Kotecha","year":"2024","unstructured":"Kotecha RS, Pieters R, Stutterheim J. KMT2A-rearranged acute lymphoblastic leukaemia. EJC Paediatric Oncology. 2024;4:100204.","journal-title":"EJC Paediatric Oncology"},{"issue":"10","key":"3192_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107791","volume":"300","author":"J Ogino","year":"2024","unstructured":"Ogino J, Dou Y. Histone methyltransferase KMT2A: developmental regulation to oncogenic transformation. J Biol Chem. 2024;300(10):107791.","journal-title":"J Biol Chem"},{"issue":"3","key":"3192_CR6","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3390\/biomedicines11030821","volume":"11","author":"M G\u00f3recki","year":"2023","unstructured":"G\u00f3recki M, Kozio\u0142 I, Kopystecka A, Budzy\u0144ska J, Zawitkowska J, Lejman M. Updates in KMT2A gene rearrangement in pediatric acute lymphoblastic leukemia. Biomedicines. 2023;11(3):821.","journal-title":"Biomedicines"},{"issue":"7951","key":"3192_CR7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41586-023-05780-8","volume":"615","author":"H Wang","year":"2023","unstructured":"Wang H, Fan Z, Shliaha PV, Miele M, Hendrickson RC, Jiang X, Helin K. H3K4me3 regulates RNA polymerase II promoter-proximal pause-release. Nature. 2023;615(7951):339\u201348.","journal-title":"Nature"},{"issue":"15","key":"3192_CR8","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1016\/j.molcel.2021.05.028","volume":"81","author":"K Zumer","year":"2021","unstructured":"Zumer K, Maier KC, Farnung L, Jaeger MG, Rus P, Winter G, Cramer P. Two distinct mechanisms of RNA polymerase II elongation stimulation in vivo. Mol Cell. 2021;81(15):3096\u2013109. e8.","journal-title":"Mol Cell"},{"key":"3192_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35332","author":"F Perner","year":"2026","unstructured":"Perner F, Gadrey JY, Armstrong SA, K\u00fchn MW. Targeting the menin\u2013KMT2A interaction in leukemia: lessons learned and future directions. Int J Cancer. 2026;158:342\u201356. https:\/\/doi.org\/10.1002\/ijc.35332.","journal-title":"Int J Cancer"},{"issue":"16","key":"3192_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25169023","volume":"25","author":"L Guarnera","year":"2024","unstructured":"Guarnera L, D\u2019Addona M, Bravo-Perez C, Visconte V. KMT2A rearrangements in leukemias: molecular aspects and therapeutic perspectives. Int J Mol Sci. 2024;25(16):9023.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3192_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/stcltm\/szae089","volume":"14","author":"A Schurer","year":"2025","unstructured":"Schurer A, Glushakow-Smith SG, Gritsman K. Targeting chromatin modifying complexes in acute myeloid leukemia. Stem Cells Transl Med. 2025;14(2):szae089.","journal-title":"Stem Cells Transl Med"},{"key":"3192_CR12","doi-asserted-by":"crossref","unstructured":"Janssens DH, Duran M, Otto DJ, Wu W, Xu Y, Kirkey D et al. KMT2A oncoproteins induce epigenetic resistance to targeted therapies. BioRxiv. 2024;573681.","DOI":"10.1101\/2023.12.29.573681"},{"issue":"5","key":"3192_CR13","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s13346-020-00863-9","volume":"11","author":"J Cao","year":"2021","unstructured":"Cao J, Bhatnagar S, Wang J, Qi X, Prabha S, Panyam J. Cancer stem cells and strategies for targeted drug delivery. Drug Deliv Transl Res. 2021;11(5):1779\u2013805.","journal-title":"Drug Deliv Transl Res"},{"key":"3192_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115110","volume":"202","author":"L Xu","year":"2022","unstructured":"Xu L, Zhang J, Sun J, Hou K, Yang C, Guo Y, et al. Epigenetic regulation of cancer stem cells: shedding light on the refractory\/relapsed cancers. Biochem Pharmacol. 2022;202:115110.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"3192_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5603\/ahp.102873","volume":"56","author":"O Izuegbuna","year":"2025","unstructured":"Izuegbuna O. KMT2a-rearranged acute leukaemias\u2014insights and potential therapeutic options. Acta Haematol Pol. 2025;56(1):22\u201338.","journal-title":"Acta Haematol Pol"},{"issue":"1","key":"3192_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01632-8","volume":"17","author":"KV Nadiminti","year":"2024","unstructured":"Nadiminti KV, Sahasrabudhe KD, Liu H. Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead. J Hematol Oncol. 2024;17(1):113.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"3192_CR17","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1038\/s41375-024-02368-7","volume":"38","author":"B Cuglievan","year":"2024","unstructured":"Cuglievan B, Kantarjian H, Rubnitz JE, Cooper TM, Zwaan CM, Pollard JA, et al. Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community. Leukemia. 2024;38(10):2073\u201384.","journal-title":"Leukemia"},{"issue":"23","key":"3192_CR18","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.3390\/cancers16234017","volume":"16","author":"S Cantilena","year":"2024","unstructured":"Cantilena S, AlAmeri M, Che N, Williams O, de Boer J. Synergistic strategies for KMT2A-Rearranged leukemias: beyond Menin inhibitor. Cancers. 2024;16(23):4017.","journal-title":"Cancers"},{"issue":"7","key":"3192_CR19","first-page":"227","volume":"13","author":"M Canichella","year":"2025","unstructured":"Canichella M, Papayannidis C, Mazzone C, de Fabritiis P. Therapeutic implications of menin inhibitors in the treatment of acute leukemia: a critical review. Dis. 2025;13(7):227.","journal-title":"Dis"},{"issue":"5","key":"3192_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/dneu.22235","volume":"75","author":"YC Huang","year":"2015","unstructured":"Huang YC, Shih HY, Lin SJ, Chiu CC, Ma TL, Yeh TH, Cheng YC. The epigenetic factor Kmt2a\/Mll1 regulates neural progenitor proliferation and neuronal and glial differentiation. Dev Neurobiol. 2015;75(5):452\u201362.","journal-title":"Dev Neurobiol"},{"key":"3192_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrrev.2022.108443","volume":"790","author":"E Poreba","year":"2022","unstructured":"Poreba E, Lesniewicz K, Durzynska J. Histone-lysine N-methyltransferase 2 (KMT2) complexes - a new perspective. Mutat Res-Rev Mutat Res. 2022;790:108443.","journal-title":"Mutat Res-Rev Mutat Res"},{"key":"3192_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/stcltm\/szae089","author":"A Schurer","year":"2025","unstructured":"Schurer A, Glushakow-Smith SG, Gritsman K. Targeting chromatin modifying complexes in acute myeloid leukemia. Stem Cells Transl Med. 2025;14(2):szae089. https:\/\/doi.org\/10.1093\/stcltm\/szae089.","journal-title":"Stem Cells Transl Med"},{"key":"3192_CR23","doi-asserted-by":"publisher","first-page":"989109","DOI":"10.3389\/fnins.2023.989109","volume":"17","author":"FD Ritchie","year":"2023","unstructured":"Ritchie FD, Lizarraga SB. The role of histone methyltransferases in neurocognitive disorders associated with brain size abnormalities. Front Neurosci. 2023;17:989109.","journal-title":"Front Neurosci"},{"issue":"13","key":"3192_CR24","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1523\/JNEUROSCI.3004-14.2015","volume":"35","author":"M Jakovcevski","year":"2015","unstructured":"Jakovcevski M, Ruan H, Shen EY, Dincer A, Javidfar B, Ma Q, et al. Neuronal Kmt2a\/Mll1 histone methyltransferase is essential for prefrontal synaptic plasticity and working memory. J Neurosci. 2015;35(13):5097\u2013108.","journal-title":"J Neurosci"},{"issue":"13","key":"3192_CR25","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1038\/npp.2016.144","volume":"41","author":"EY Shen","year":"2016","unstructured":"Shen EY, Jiang Y, Javidfar B, Kassim B, Loh YE, Ma Q, et al. Neuronal deletion of Kmt2a\/Mll1 histone methyltransferase in ventral striatum is associated with defective spike-timing-dependent striatal synaptic plasticity, altered response to dopaminergic drugs, and increased anxiety. Neuropsychopharmacology. 2016;41(13):3103\u201313.","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"3192_CR26","doi-asserted-by":"publisher","first-page":"7611","DOI":"10.1093\/nar\/gku458","volume":"42","author":"A Ali","year":"2014","unstructured":"Ali A, Veeranki SN, Tyagi S. A SET-domain-independent role of WRAD complex in cell-cycle regulatory function of mixed lineage leukemia. Nucleic Acids Res. 2014;42(12):7611\u201324.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3192_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0802-2","volume":"12","author":"WJ Lavery","year":"2020","unstructured":"Lavery WJ, Barski A, Wiley S, Schorry EK, Lindsley AW. KMT2C\/D COMPASS complex-associated diseases [K(CD)COM-ADs]: an emerging class of congenital regulopathies. Clin Epigenetics. 2020;12(1):10.","journal-title":"Clin Epigenetics"},{"issue":"2","key":"3192_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1101\/gad.254870.114","volume":"29","author":"P Zhang","year":"2015","unstructured":"Zhang P, Chaturvedi CP, Tremblay V, Cramet M, Brunzelle JS, Skiniotis G, Brand M, Shilatifard A, Couture JF. A phosphorylation switch on RbBP5 regulates histone H3 Lys4 methylation. Genes Dev. 2015;29(2):123\u20138.","journal-title":"Genes Dev"},{"key":"3192_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cells11091450","author":"M Ma","year":"2022","unstructured":"Ma M, Zhou J, Ma Z, Chen H, Li L, Hou L, et al. The Ash2l SDI domain is required to maintain the stability and binding of DPY30. Cells. 2022;11(9):1450. https:\/\/doi.org\/10.3390\/cells11091450.","journal-title":"Cells"},{"issue":"38","key":"3192_CR30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2205691119","volume":"119","author":"S Rahman","year":"2022","unstructured":"Rahman S, Hoffmann NA, Worden EJ, Smith ML, Namitz KEW, Knutson BA, et al. Multistate structures of the MLL1-WRAD complex bound to H2B-ubiquitinated nucleosome. Proc Natl Acad Sci U S A. 2022;119(38):e2205691119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3192_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.canlet.2019.05.024","volume":"458","author":"RJ Fagan","year":"2019","unstructured":"Fagan RJ, Dingwall AK. COMPASS ascending: emerging clues regarding the roles of MLL3\/KMT2C and MLL2\/KMT2D proteins in cancer. Cancer Lett. 2019;458:56\u201365.","journal-title":"Cancer Lett"},{"issue":"7","key":"3192_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2024.168453","volume":"436","author":"HT Van","year":"2024","unstructured":"Van HT, Xie G, Dong P, Liu Z, Ge K. KMT2 family of H3K4 methyltransferases: enzymatic activity-dependent and -independent functions. J Mol Biol. 2024;436(7):168453.","journal-title":"J Mol Biol"},{"issue":"7","key":"3192_CR33","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1101\/gr.268490.120","volume":"31","author":"JR Harman","year":"2021","unstructured":"Harman JR, Thorne R, Jamilly M, Tapia M, Crump NT, Rice S, et al. A KMT2A-AFF1 gene regulatory network highlights the role of core transcription factors and reveals the regulatory logic of key downstream target genes. Genome Res. 2021;31(7):1159\u201373.","journal-title":"Genome Res"},{"key":"3192_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16234017","author":"S Cantilena","year":"2024","unstructured":"Cantilena S, AlAmeri M, Che N, Williams O, de Boer J. Synergistic strategies for KMT2A-rearranged leukemias: beyond menin inhibitor. Cancers (Basel). 2024;16(23):4017. https:\/\/doi.org\/10.3390\/cancers16234017.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"3192_CR35","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nrc3929","volume":"15","author":"RC Rao","year":"2015","unstructured":"Rao RC, Dou Y. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat Rev Cancer. 2015;15(6):334\u201346.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3192_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-022-04651-1","volume":"80","author":"AM Stroynowska-Czerwinska","year":"2023","unstructured":"Stroynowska-Czerwinska AM, Klimczak M, Pastor M, Kazrani AA, Misztal K, Bochtler M. Clustered PHD domains in KMT2\/MLL proteins are attracted by H3K4me3 and H3 acetylation-rich active promoters and enhancers. Cell Mol Life Sci. 2023;80(1):23.","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"3192_CR37","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s44318-024-00329-5","volume":"44","author":"J Zhang","year":"2025","unstructured":"Zhang J, Sun Q, Liu L, Yang S, Zhang X, Miao YL, Liu X. Histone methyltransferases MLL2 and SETD1A\/B play distinct roles in H3K4me3 deposition during the transition from totipotency to pluripotency. EMBO J. 2025;44(2):437\u201356.","journal-title":"EMBO J"},{"issue":"5","key":"3192_CR38","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.cancergen.2015.01.005","volume":"208","author":"DJ Ford","year":"2015","unstructured":"Ford DJ, Dingwall AK. The cancer COMPASS: navigating the functions of MLL complexes in cancer. Cancer Genet. 2015;208(5):178\u201391.","journal-title":"Cancer Genet"},{"issue":"1","key":"3192_CR39","doi-asserted-by":"publisher","first-page":"5685","DOI":"10.1038\/s41467-023-41297-4","volume":"14","author":"MA Mouti","year":"2023","unstructured":"Mouti MA, Deng S, Pook M, Malzahn J, Rendek A, Militi S, et al. KMT2A associates with PHF5A-PHF14-HMG20A-RAI1 subcomplex in pancreatic cancer stem cells and epigenetically regulates their characteristics. Nat Commun. 2023;14(1):5685.","journal-title":"Nat Commun"},{"key":"3192_CR40","doi-asserted-by":"crossref","unstructured":"Guarnera L, D\u2019Addona M, Bravo-Perez C, Visconte V. KMT2A rearrangements in leukemias: molecular aspects and therapeutic perspectives. Int J Mol Sci. 2024; 25(16):9023.","DOI":"10.3390\/ijms25169023"},{"key":"3192_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.05.011","author":"M Yagi","year":"2025","unstructured":"Yagi M, Bonilla G, Hoetker MS, Tsopoulidis N, Horng JE, Haggerty C et al. Bivalent chromatin instructs lineage specification during hematopoiesis. Cell. 2025;188(16):4314\u20134331.e29. https:\/\/doi.org\/10.1016\/j.cell.2025.05.011.","journal-title":"Cell"},{"issue":"12","key":"3192_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2023.104869","volume":"66","author":"KL Juul-Dam","year":"2023","unstructured":"Juul-Dam KL, Shukla NN, Cooper TM, Cuglievan B, Heidenreich O, Kolb EA, et al. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX\/MEIS1 expression. Eur J Med Genet. 2023;66(12):104869.","journal-title":"Eur J Med Genet"},{"issue":"14","key":"3192_CR43","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1182\/blood.2021013442","volume":"139","author":"C Chen","year":"2022","unstructured":"Chen C, Yu W, Alikarami F, Qiu Q, Chen CH, Flournoy J, et al. Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia. Blood. 2022;139(14):2198\u2013211.","journal-title":"Blood"},{"issue":"1","key":"3192_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40487-024-00262-x","volume":"12","author":"X Thomas","year":"2024","unstructured":"Thomas X. Small molecule Menin inhibitors: novel therapeutic agents targeting acute myeloid leukemia with KMT2A rearrangement or NPM1 mutation. Oncol Ther. 2024;12(1):57\u201372.","journal-title":"Oncol Ther"},{"issue":"8","key":"3192_CR45","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1182\/bloodadvances.2024015527","volume":"9","author":"O Okeleji","year":"2025","unstructured":"Okeleji O, McCall D, Gibson A, Garcia MB, Nunez C, Roth M, et al. Post transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia. Blood Adv. 2025;9(8):1988\u201390.","journal-title":"Blood Adv"},{"issue":"4","key":"3192_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/jdb9040044","volume":"9","author":"F Blasi","year":"2021","unstructured":"Blasi F, Bruckmann C. MEIS1 in hematopoiesis and cancer. How MEIS1-PBX interaction can be used in therapy. J Dev Biol. 2021;9(4):44.","journal-title":"J Dev Biol"},{"issue":"8","key":"3192_CR47","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3390\/life11080823","volume":"11","author":"A Klonou","year":"2021","unstructured":"Klonou A, Chlamydas S, Piperi C. Structure, activity and function of the MLL2 (KMT2B) protein lysine methyltransferase. Life. 2021;11(8):823.","journal-title":"Life"},{"issue":"1","key":"3192_CR48","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s43587-023-00549-0","volume":"4","author":"M Li","year":"2024","unstructured":"Li M, Guo H, Carey M, Huang C. Transcriptional and epigenetic dysregulation impairs generation of proliferative neural stem and progenitor cells during brain aging. Nat Aging. 2024;4(1):62\u201379.","journal-title":"Nat Aging"},{"key":"3192_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1559183","volume":"13","author":"W Bae","year":"2025","unstructured":"Bae W, Ra EA, Lee MH. Epigenetic regulation of reprogramming and pluripotency: insights from histone modifications and their implications for cancer stem cell therapies. Front Cell Dev Biol. 2025;13:1559183.","journal-title":"Front Cell Dev Biol"},{"key":"3192_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02665-9","author":"AS Calder\u00f3n","year":"2025","unstructured":"Calder\u00f3n AS, Ghazanfari R, Masoumi Z, Kharazi S, Palo S, Lang S, et al. Ontogeny-specific induction of the KMT2A:: AFF1-fusion drives development of a distinct CD24 positive pre-leukemic state. Leukemia. 2025;39:2099\u2013111. https:\/\/doi.org\/10.1038\/s41375-025-02665-9.","journal-title":"Leukemia"},{"issue":"1","key":"3192_CR51","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.tig.2019.10.004","volume":"36","author":"M Wooten","year":"2020","unstructured":"Wooten M, Ranjan R, Chen X. Asymmetric histone inheritance in asymmetrically dividing stem cells. Trends Genet. 2020;36(1):30\u201343.","journal-title":"Trends Genet"},{"key":"3192_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35332","author":"F Perner","year":"2025","unstructured":"Perner F, Gadrey JY, Armstrong SA, Kuhn MWM. Targeting the menin-KMT2A interaction in leukemia: lessons learned and future directions. Int J Cancer. 2026;158(2):342\u201356. https:\/\/doi.org\/10.1002\/ijc.35332.","journal-title":"Int J Cancer"},{"issue":"20","key":"3192_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70326","volume":"13","author":"L Yin","year":"2024","unstructured":"Yin L, Wan L, Zhang Y, Hua S, Shao X. Recent developments and evolving therapeutic strategies in KMT2A-rearranged acute leukemia. Cancer Med. 2024;13(20):e70326.","journal-title":"Cancer Med"},{"issue":"11","key":"3192_CR54","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1038\/s41379-020-0582-4","volume":"33","author":"LR Massoth","year":"2020","unstructured":"Massoth LR, Hung YP, Nardi V, Nielsen GP, Hasserjian RP, Louissaint A Jr., et al. <article-title update=\"added\">Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1\u2013KMT2A\u2013YAP1 and VIM\u2013KMT2A fusions. Mod Pathol. 2020;33(11):2307\u201317.","journal-title":"Mod Pathol"},{"issue":"1","key":"3192_CR55","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40364-020-00241-0","volume":"8","author":"R Zhang","year":"2020","unstructured":"Zhang R, Wu HX, Xu M, Xie X. KMT2A\/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors. Biomark Res. 2020;8(1):71.","journal-title":"Biomark Res"},{"issue":"7954","key":"3192_CR56","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615(7954):920\u20134.","journal-title":"Nature"},{"issue":"1","key":"3192_CR57","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3324\/haematol.2020.271619","volume":"107","author":"T Milan","year":"2020","unstructured":"Milan T, Celton M, Lagac\u00e9 K, Roques \u00c9, Safa-Tahar-Henni S, Bresson E, et al. Epigenetic changes in human model KMT2A leukemias highlight early events during leukemogenesis. Haematologica. 2020;107(1):86.","journal-title":"Haematologica"},{"key":"3192_CR58","doi-asserted-by":"crossref","unstructured":"Schrezenmeier J, Huntly B. Epigenetic dysregulation in acute myeloid Leukemia, seminars in hematology. Elsevier; 2025.","DOI":"10.1053\/j.seminhematol.2025.06.003"},{"issue":"34","key":"3192_CR59","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1038\/s41388-018-0273-5","volume":"37","author":"K Gala","year":"2018","unstructured":"Gala K, Li Q, Sinha A, Razavi P, Dorso M, Sanchez-Vega F, et al. KMT2C mediates the estrogen dependence of breast cancer through regulation of ER\u03b1 enhancer function. Oncogene. 2018;37(34):4692\u2013710.","journal-title":"Oncogene"},{"issue":"21","key":"3192_CR60","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf2567","volume":"7","author":"C Wan","year":"2021","unstructured":"Wan C, Mahara S, Sun C, Doan A, Chua HK, Xu D, et al. Genome-scale CRISPR-Cas9 screen of Wnt\/\u03b2-catenin signaling identifies therapeutic targets for colorectal cancer. Sci Adv. 2021;7(21):eabf2567.","journal-title":"Sci Adv"},{"issue":"38","key":"3192_CR61","doi-asserted-by":"publisher","first-page":"63110","DOI":"10.18632\/oncotarget.18668","volume":"8","author":"Y-C Huang","year":"2017","unstructured":"Huang Y-C, Lin S-J, Shih H-Y, Chou C-H, Chu H-H, Chiu C-C, Yuh C-H, Yeh T-H, Cheng Y-C. Epigenetic regulation of NOTCH1 and NOTCH3 by KMT2A inhibits glioma proliferation. Oncotarget. 2017;8(38):63110.","journal-title":"Oncotarget"},{"issue":"1","key":"3192_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-022-00565-3","volume":"13","author":"NC Whitlock","year":"2022","unstructured":"Whitlock NC, White ME, Capaldo BJ, Ku AT, Agarwal S, Fang L, et al. Progression of prostate cancer reprograms MYC-mediated lipid metabolism via lysine methyltransferase 2A. Discov Oncol. 2022;13(1):97.","journal-title":"Discov Oncol"},{"issue":"7","key":"3192_CR63","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1002\/cam4.2226","volume":"8","author":"Y Fang","year":"2019","unstructured":"Fang Y, Zhang D, Hu T, Zhao H, Zhao X, Lou Z, et al. KMT2A histone methyltransferase contributes to colorectal cancer development by promoting cathepsin Z transcriptional activation. Cancer Med. 2019;8(7):3544\u201352.","journal-title":"Cancer Med"},{"key":"3192_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2025.107924","author":"X Yang","year":"2025","unstructured":"Yang X, Huang R. Menin inhibitors in KMT2A-rearranged leukemia: mechanistic insights, clinical trial progress, and potential of combination therapies. Leuk Res. 2025:157:107924. https:\/\/doi.org\/10.1016\/j.leukres.2025.107924.","journal-title":"Leuk Res"},{"key":"3192_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104783","volume":"213","author":"SA Dali","year":"2025","unstructured":"Dali SA, Al-Mashdali AF, Kalfah A, Mohamed SF. Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: a scoping review of safety and efficacy. Crit Rev Oncol Hematol. 2025;213:104783.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"3192_CR66","first-page":"1278","volume":"110","author":"SM Hogeling","year":"2025","unstructured":"Hogeling SM, Le DM, La Rose N, Kwon MC, Wierenga ATJ, Van den Heuvel FAJ, et al. Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia. Haematologica. 2025;110(6):1278\u201391.","journal-title":"Haematologica"},{"issue":"11","key":"3192_CR67","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1182\/blood.2023022480","volume":"144","author":"MC Kwon","year":"2024","unstructured":"Kwon MC, Thuring JW, Querolle O, Dai X, Verhulst T, Pande V, et al. <article-title update=\"added\">Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A - and NPM1 -altered leukemias. Blood. 2024;144(11):1206\u201320.","journal-title":"Blood"},{"key":"3192_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16223743","author":"S Dhiman","year":"2024","unstructured":"Dhiman S, Dhillon V, Balasubramanian SK. Targeting menin in acute myeloid leukemia: therapeutic advances and future directions. Cancers (Basel). 2024;16(22):3743. https:\/\/doi.org\/10.3390\/cancers16223743.","journal-title":"Cancers (Basel)"},{"issue":"26","key":"3192_CR69","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.18632\/oncotarget.26811","volume":"10","author":"Y Ueno","year":"2019","unstructured":"Ueno Y, Mori M, Kamiyama Y, Saito R, Kaneko N, Isshiki E, Kuromitsu S, Takeuchi M. Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD(+) acute myeloid leukemia. Oncotarget. 2019;10(26):2530\u201345.","journal-title":"Oncotarget"},{"issue":"35","key":"3192_CR70","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1200\/JCO.22.00602","volume":"40","author":"N Daver","year":"2022","unstructured":"Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, et al. Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia. J Clin Oncol. 2022;40(35):4048\u201359.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3192_CR71","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13046-024-03188-4","volume":"43","author":"D Wang","year":"2024","unstructured":"Wang D, Chen J, Wu G, Xiong F, Liu W, Wang Q, et al. MBD2 regulates the progression and chemoresistance of cholangiocarcinoma through interaction with WDR5. J Exp Clin Cancer Res. 2024;43(1):272.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"3192_CR72","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","volume":"36","author":"AV Krivtsov","year":"2019","unstructured":"Krivtsov AV, Evans K, Gadrey JY, Eschle BK, Hatton C, Uckelmann HJ, et al. A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia. Cancer Cell. 2019;36(6):660-673 e11.","journal-title":"Cancer Cell"},{"issue":"4","key":"3192_CR73","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","volume":"27","author":"D Borkin","year":"2015","unstructured":"Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J, et al. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell. 2015;27(4):589\u2013602.","journal-title":"Cancer Cell"},{"issue":"2","key":"3192_CR74","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1172\/JCI129126","volume":"130","author":"S Klossowski","year":"2020","unstructured":"Klossowski S, Miao H, Kempinska K, Wu T, Purohit T, Kim E, et al. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J Clin Invest. 2020;130(2):981\u201397.","journal-title":"J Clin Invest"},{"issue":"7","key":"3192_CR75","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28284","volume":"67","author":"RT Kurmasheva","year":"2020","unstructured":"Kurmasheva RT, Bandyopadhyay A, Favours E, Pozo VD, Ghilu S, Phelps DA, et al. Evaluation of VTP-50469, a menin-MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium. Pediatr Blood Cancer. 2020;67(7):e28284.","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"3192_CR76","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1038\/leu.2014.119","volume":"28","author":"W Fiskus","year":"2014","unstructured":"Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K, Iyer SP, Bearss D, Bhalla KN. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia. 2014;28(11):2155\u201364.","journal-title":"Leukemia"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03192-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03192-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03192-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T16:04:32Z","timestamp":1770393872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03192-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":76,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["3192"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03192-4","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with animals\/human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"No.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}}],"article-number":"62"}}